Document is current

Article History

Received: 29 July 2025

Accepted: 27 October 2025

First Online: 28 November 2025

Declarations

:

: This study was approved by the Ethics Committee for Research with medicinal products of Galicia (2020/248), the Ethics Committee for Research with medicinal products of Euskadi (EPA2020065), the Ethics Committee for Research with medicinal products of Cantabria, the Ethics Committee for Research with medicinal products of Hospital Universitario La Paz (PI-4313), the Ethics Committee for Research with medicinal products of Córdoba (1584-N-20), and the Ethics Committee for Research at Hospital Universitario Elche-Vinalopó. The study was conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All living patients provided written informed consent before enrollment. Informed consent was waived for deceased patients before study initiation.

: Not applicable.

: Natalia Fernández-Díaz — Travel, accommodations, and expenses: GlaxoSmithKline, Lilly, Roche, Pierre Fabre, Novartis, and Sanofi; María Mateos-González — Travel, accommodations, and expenses: AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda; Educational activities: AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Takeda; Honoraria for consultancies: MSD; Isabel Chirivella-González — Travel, accommodations, and expenses: Pfizer, Bristol-Myers Squibb, MSD, and Ipsen; Honoraria for consultancies: Pfizer, Bristol-Myers Squibb, Ipsen, MSD, and Roche; Honoraria as speaker: Pfizer, Bristol-Myers Squibb, and Ipsen; Ovidio Fernández-Calvo — Travel, accommodations, and expenses: Bristol-Myers Squibb, Ipsen, and Astellas; Honoraria for consultancies: Astellas, Pfizer, Bristol-Myers Squibb, Ipsen, Merck, and Eisai; Honoraria as speaker: Novartis, Bristol-Myers Squibb, Ipsen, Roche, Astellas, and Bayer; Martín Lázaro-Quintela — Honoraria as speaker: MSD, Bristol-Myers Squibb, and Ipsen; Advisory board: Ipsen, Astellas; Aurea Molina-Díaz — Travel, accommodations, and expenses: Eisai, Grünenthal Pharma, Kyowa Kirin, PharmaMar, Merck, Bristol-Myers Squibb, Roche, and Ipsen; Honoraria for educational activities: Pfizer, Bristol-Myers Squibb, MSD, Eisai, Kyowa Kirin, Merck, PharmaMar, AstraZeneca, Lilly, Sanofi, Takeda, Astellas, Roche, and Pierre Fabre; Advisory board: Bayer, Eisai, Pierre Fabre, PharmaMar, Pfizer, and Merck; Santiago Aguín-Losada — Travel, accommodations, and expenses: Merck, Roche, Bristol-Myers Squibb, and MSD; Honoraria for educational activities: Merck, MSD, Bristol-Myers Squibb, Sanofi, Roche, and Lilly; Honoraria for consultancies: Merck, MSD, and Bristol-Myers Squibb; Luis León-Mateos — Travel, accommodations, and expenses: Bristol-Myers Squibb, Lilly, MSD, Pfizer, and Roche; Honoraria for educational activities: AstraZeneca, Boehringer Ingelheim, Novartis, Janssen, Astellas, Pfizer, and Sanofi; Honoraria for consultancies: AstraZeneca, Boehringer Ingelheim, Novartis, Janssen, Astellas, Pfizer, and Sanofi; Jorge García-González — Travel, accommodations, and expenses: AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda; Honoraria for educational activities: AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Takeda; Honoraria for consultancies: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Roche, Sanofi, and Takeda; Ignacio Duran — Travel, accommodations, and expenses: Bayer, AstraZeneca, and Merck; Honoraria for educational activities: Astellas, Bristol-Myers Squibb, Merck, Ipsen, Janssen, MSD, and Genentech; Honoraria for consultancies: Astellas, MSD, Merck, Bristol-Myers Squibb, Ipsen, AstraZeneca, and Janssen; Institutional research funding: Genentech and AstraZeneca; Rafael López-López — Travel, accommodations, and expenses: Lilly, Novartis, Pfizer, Merck, Roche, and Bristol-Myers Squibb; Honoraria for educational activities: Lilly, Novartis, Pfizer, Merck, Roche, and Bristol-Myers Squibb; Honoraria for consultancies: PharmaMar, Bayer, and Pierre Fabre; Urbano Anido-Herranz — Travel, accommodations, and expenses: Ipsen, Bayer, Merck, Pfizer, and Sanofi; Honoraria for educational activities: Advanced Accelerator Applications (Novartis), Bayer, Ipsen, MSD, AstraZeneca, Merck, Eisai, Bristol-Myers Squibb, Kyowa Kirin, Rovi, GlaxoSmithKline, and LEO Pharma; Honoraria for consultancies: Advanced Accelerator Applications (Novartis), Ipsen, AstraZeneca, Merck, Pfizer, Astellas, and Bayer; Juan Ruiz-Bañobre — Travel, accommodations, and expenses: Merck, Pierre Fabre, Sanofi, Seagen, and MSD; Honoraria for educational activities: Ipsen; Institutional research funding: Nouscom, Pfizer, Roche, and GlaxoSmithKline. The other authors have no conflicts of interest to declare.